<- Go Home
Evofem Biosciences, Inc.
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Market Cap
$1.1M
Volume
859.5K
Cash and Equivalents
N/A
EBITDA
-$9.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$13.8M
Profit Margin
80.84%
52 Week High
$0.04
52 Week Low
$0.01
Dividend
N/A
Price / Book Value
-0.01
Price / Earnings
-0.03
Price / Tangible Book Value
-0.01
Enterprise Value
$50.4M
Enterprise Value / EBITDA
-5.48
Operating Income
-$10.1M
Return on Equity
13.15%
Return on Assets
-33.72
Cash and Short Term Investments
$202.0K
Debt
$44.8M
Equity
-$66.1M
Revenue
$17.1M
Unlevered FCF
$3.0M
Sector
Pharmaceuticals
Category
N/A